SEC Form 10-Q filed by Fate Therapeutics Inc.
$FATE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/18/2024 | Underperform → Neutral | BofA Securities | |
| 6/17/2024 | $4.00 → $6.00 | Neutral → Overweight | Piper Sandler |
| 3/27/2023 | $6.00 | Equal Weight | Wells Fargo |
| 1/24/2023 | $115.00 → $7.00 | Buy → Neutral | H.C. Wainwright |
| 1/6/2023 | $20.00 → $7.00 | Outperform → Market Perform | BMO Capital Markets |
| 1/6/2023 | $71.00 → $12.00 | Overweight → Neutral | Piper Sandler |
| 1/6/2023 | Outperform → Market Perform | Cowen | |
| 1/6/2023 | $107.00 → $5.30 | Buy → Hold | Stifel |
BofA Securities upgraded Fate Therapeutics from Underperform to Neutral
Piper Sandler upgraded Fate Therapeutics from Neutral to Overweight and set a new price target of $6.00 from $4.00 previously
Wells Fargo resumed coverage of Fate Therapeutics with a rating of Equal Weight and set a new price target of $6.00
SCHEDULE 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)
10-Q - FATE THERAPEUTICS INC (0001434316) (Filer)
8-K - FATE THERAPEUTICS INC (0001434316) (Filer)
4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- USA News Group News Commentary – Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the gap, with oncology ventures securing hundreds of millions in funding so far in 2025. The Senate's recent restoration of $15 million for the Pancreatic Cancer Research Program (PCARP) was a win, yet its earlier elimination underscored the fragility of public support. Against this backdrop, investors are zeroing in on companies with standout science, solid pipelines, and clear regulatory strategies, including Onc
First patient treated with FT819 off-the-shelf CAR T-cell product candidate following fludarabine-free conditioning for severe lupus nephritis demonstrated durability of response with drug-free definition of remission in systemic lupus erythematosus (DORIS) at 12-month follow-up Held initial discussion with FDA under FT819 RMAT designation to seek feedback on registrational pathway in moderate-to-severe Systemic Lupus Erythematosus (SLE) and refractory Lupus Nephritis (LN) First extrarenal SLE patient treated with FT819 in the absence of conditioning, and as add-on to standard-of-care maintenance therapy, achieved Low Lupus Disease Activity State (LLDAS) at 3- and 6-month follow-up IND ap
SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on August 4, 2025 the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 60,000 shares of the Company's common stock at an exercise price per share of $1.06, which was the closing price per share of the Company's common stock as reported by NASDAQ on August 4, 2025, the options grant date, and (ii) restricted stock u
4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
3 - FATE THERAPEUTICS INC (0001434316) (Issuer)
First Lupus Patient Treated with FT819 CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Future Clinical Development of FT819 to Focus Exclusively on Autoimmune Disease Enrollment Initiated with FT522 CAR NK Cell Product Candidate in Conditioning-free Treatment Arm of Phase 1 B Cell Lymphoma Study First Patient Treated with FT825 / ONO-8250 CAR T-cell Product Candidate in Phase 1 Solid Tumor Study $391 Million in Cash, Cash Equivalents, and Investments SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPS
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, will host a conference call and live audio webcast on Thursday, May 9, 2024 at 5:00 PM ET to report its first quarter 2024 financial results and highlight operational updates, including a review of its FT819 and FT522 programs for autoimmune diseases being featured on the same day at the American Society of Gene and Cell Therapy 27th Annual Meeting. In order
CIRM Grant Awarded to Support Phase 1 Autoimmunity Study of FT819 CD19-targeted CAR T-cell Program for Systemic Lupus Erythematosus; Study Start-up Ongoing at Multiple Clinical Sites First Patient Treated in Phase 1 Study of FT522 ADR-armed, CD19-targeted CAR NK Cell Program; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Chemotherapy Conditioning Phase 1 Study Initiated of FT825 / ONO-8250 CAR T-cell Program for Solid Tumors; Incorporates Seven Synthetic Controls including Novel Cancer-specific CAR Targeting HER2 $316 Million in Cash, Cash Equivalents, and Investments SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FA
SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Matthew Abernethy, M.B.A., to its Board of Directors effective as of May 29, 2025. Mr. Abernethy brings to the Company over 15 years' experience in corporate finance and investor relations in the biotech and medical device industry. In addition, the Company announced that Timothy P. Coughlin stepped down from the Board of Directors, effective concurrently with Mr. Abernethy's appointment. "Mr. Aberne
Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025 Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE) ("Fate Therapeutics" or the "Company"), a clinical-stage biopharmaceutical company dedicated to bringing first-in-class induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that Scott Wolchko, the Company's President and CEO, will retire effective December 31, 2024. Fate's current President of Research and Development (R&D), Bob Vala
SAN DIEGO, July 31, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced the appointment of Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors effective immediately. Dr. Mozaffarian brings to the Company medical and scientific leadership in the field of immunology and autoimmunity, with over 20 years of research and industry experience in the discovery, development, and commercialization of novel small and large molecule therapeutics. "Dr. Moza
SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)
SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)
SC 13D/A - FATE THERAPEUTICS INC (0001434316) (Subject)